Login to Your Account



Clinic Roundup


Friday, September 23, 2011
Advanced Cell Technology Inc., of Marlborough, Mass., has received clearance from the UK Medicines and Healthcare products Regulatory Agency to treat patients as part of a Phase I/II trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription